Harrow Health, Inc. (NASDAQ: HROW) owns a portfolio of healthcare businesses, including the nationâs leading ophthalmology pharmaceutical compounding business, ImprimisRx. The company holds large equity positions in Eton Pharmaceuticals, Surface Pharmaceuticals, Melt Pharmaceuticals, Mayfield Pharmaceuticals and Radley Pharmaceuticals, companies founded as subsidiaries of Harrow Health. The Company also owns royalty rights in certain 505(b)(2) drug candidates being developed by Eton, Surface, Melt, Mayfield and Radley. Harrow intends to create, invest in and grow paradigm shifting health care businesses that put patients first. Source
No articles found.
Global leader in therapeutic ultrasound and present in the market for more than 35...
Global leader in therapeutic ultrasound and pre...
We're developing Vipax, the world's first portable, shelf-stable, broad-spectrum a...
We're developing Vipax, the world's first porta...
Otonomy is a biopharmaceutical company dedicated to the development of innovative ...
Otonomy is a biopharmaceutical company dedicate...
Blueprint Medicines is a precision therapy company striving to improve human healt...
Blueprint Medicines is a precision therapy comp...
Founded in 1998, GW is a biopharmaceutical company focused on discovering, develop...
Founded in 1998, GW is a biopharmaceutical comp...
Join the National Investor Network and get the latest information with your interests in mind.